Table 1.
Quality assessment and risk of bias evaluation for each included study based on the Stroke Therapy Academic Industry Roundtable (STAIR) criteria
| Quality Assessment by STAIR criteria | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| study name | A | B | C | D | E | F | G | H | total score |
| Yang et al. [14] (2020) | No | No | No | Yes | Yes | Yes | Yes | Yes | 5 |
| Bai et al. [15] (2017) | Yes | No | Yes | No | Yes | Yes | No | Yes | 5 |
| Caltana et al. [16] (2015) | No | Yes | Yes | Yes | Yes | No | Yes | No | 5 |
| Sun et al. [17] (2013) | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | 7 |
| Yokubaitis et al. [18] (2021) | No | Yes | No | No | Yes | Yes | No | Yes | 4 |
| Yang et al. [19] (2017) | Yes | Yes | Yes | No | Yes | Yes | Yes | No | 6 |
| Pottier et al. [20] (2017) | No | No | No | Yes | Yes | No | No | Yes | 3 |
| Ronca et al. [21] (2015) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Yu et al. [22] (2015) | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 6 |
| Choi et al. [23] (2013) | No | Yes | No | No | Yes | Yes | No | Yes | 4 |
| Zarruk et al. [24] (2012) | Yes | Yes | Yes | No | Yes | Yes | No | Yes | 6 |
| Shirazi et al. [25] (2021) | No | No | Yes | No | Yes | Yes | Yes | Yes | 5 |
| Murakami et al. [26] (2013) | No | Yes | No | No | Yes | Yes | No | Yes | 4 |
| Suzuki et al. [27] (2012) | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Schmidt et al. [28] (2012) | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 6 |
| Reichenbach et al. [29] (2016) | No | Yes | No | No | Yes | No | Yes | No | 3 |
| Jalin et al. [30] (2015) | Yes | No | Yes | No | Yes | Yes | No | Yes | 5 |
| Bravo-Ferrer et al. [31] (2016) | No | Yes | No | Yes | Yes | Yes | Yes | Yes | 6 |
| Zhang et al. [32] (2012) | No | Yes | No | No | Yes | Yes | Yes | Yes | 5 |
| Zhang et al. [33] (2009) | No | Yes | No | No | Yes | No | Yes | Yes | 4 |
| Zhang et al. [34] (2007) | No | Yes | No | Yes | Yes | Yes | Yes | Yes | 6 |
| Zhang et al. [35] (2008) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Hu et al. [36] (2010) | Yes | Yes | Yes | No | Yes | No | No | No | 4 |
| Berger et al. [37] (2004) | Yes | Yes | No | No | Yes | No | No | No | 3 |
| Muthian et al. [38] (2004) | Yes | Yes | No | No | Yes | Yes | Yes | No | 5 |
| Hayakawa et al. [39] (2007) | No | Yes | No | No | Yes | Yes | Yes | Yes | 5 |
| Leker et al. [40] (2003) | No | Yes | Yes | No | Yes | Yes | No | Yes | 5 |
Stroke Therapy Academic Industry Roundtable (STAIR) criteria: A, implementation of randomization to minimize selection bias; B, continuous temperature monitoring to control for confounding variables; C, blinding of outcome assessment to mitigate performance bias, D, evaluation at both acute and subacute/chronic phases to capture comprehensive outcomes; E, assessment beyond infarct size to consider broader impact measures; F, testing multiple doses to elucidate dose-response relationships; G, repeated outcome assessments at various time points to validate findings longitudinally; H, therapeutic time window relationship of a particular agonist conducted.